Investors & Media

BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 9, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Barclays Gene Editing & Gene Therapy Summit Date: Monday, November 15 th at 10:30

Conference Call and Webcast Scheduled for 9:15 a.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.

- Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated - All four patients in the first two dose cohorts exhibited above normal α-Gal A activity, which was maintained for up to one year for the first patient treated - Based on these data, Sangamo has

BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 28, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021 .

BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 31, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences: 2021 Virtual Wells Fargo Healthcare Conference Date: Friday,

BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 9, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11 th at 2:55pm Eastern Time .

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time   BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 5, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results.

BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 29, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021 .

BRISBANE, Calif. --(BUSINESS WIRE)--May 24, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021 . Ms.

BRISBANE, Calif. --(BUSINESS WIRE)--May 21, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4 th at 11am Eastern Time .